References
- Kraut H, Frey E K, Werle E.. Der nachweis eines kreislauf-hormons in der pankreasdrüse. Hoppeseylers Z Physiol Chem. 1930; 189: 97–106
- Werle E.. Zur Kenntnis des haushalts des Kallikreins. Biochem Z. 1934; 269: 415–34
- Fiedler F.. Enzymology of glandular kallikreins. Erdos E G. Handbook of Experimental Pharmacology Supplement, Bradykinin, Kallidin, and Kallikrein. Pp. 103–61, New York, Springer-Verlag. 1979
- Kaplan A P, Silverberg M.. The coagulation-kinin pathway of human plasma. Blood. 1987; 70: 1–15. [PUBMED], [INFOTRIEVE]
- Asakai R, Davie E W, Chung D W.. Organization of the gene for human factor XI. Biochemistry. 1987; 26: 7221–8. [PUBMED]
- Evans B A, Yun Z X, Close J A, et al, Structure and chromosomal localization of the human renal kallikrein gene. Biochemistry. 1988; 27: 3124–9. [PUBMED]
- Clements J A.. The glandular kallikrein family of enzymes: Tissue-specific expression and hormonal regulation. Endocr Rev. 1989; 10: 393–419. [PUBMED], [INFOTRIEVE]
- Clements J A.. The molecular biology of the kallikreins and their roles in inflammation, Farmer S. The Kinin system. Pp. 71–97, New York, Academic Press. 1997
- Bhoola K D, Figueroa C D, Worthy K.. Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev. 1992; 44: 1–80. [PUBMED], [INFOTRIEVE]
- Yousef G M, Diamandis E P.. The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev. 2001; 22: 184–204. [CROSSREF], [PUBMED]
- Berg T, Bradshaw R A, Carretero O A, et al, A common nomenclature for members of the tissue (glandular) kallikrein gene families. Agents Actions Suppl. 1992; 38 (Pt 1): 19–25
- Diamandis E P, Yousef G M, Clements J, et al, New nomenclature for the human tissue kallikrein gene family. Clin Chem. 2000; 46: 1855–8. [PUBMED], [INFOTRIEVE]
- Evans B A, Drinkwater C C, Richards R I.. Mouse glandular kallikrein genes: Structure and partial sequence analysis of the kallikrein gene locus. J Biol Chem. 1987; 262: 8027–34. [PUBMED]
- Olsson A Y, Lundwall A.. Organization and evolution of the glandular kallikrein locus in Mus musculus. Biochem Biophys Res Commun. 2002; 299: 305–11. [PUBMED]
- Riegman P H, Vlietstra R J, Suurmeijer L, et al, Characterization of the human kallikrein locus. Genomics. 1992; 14: 6–11. [PUBMED]
- Southard-Smith M, Pierce J C, MacDonald R J.. Physical mapping of the rat tissue kallikrein family in two gene clusters by analysis of P1 bacteriophage clones. Genomics. 1994; 22: 404–17. [CROSSREF], [PUBMED]
- Kurtz T W, St, Lezin E M.. Gene mapping in experimental hypertension. J Am Soc Nephrol. 1992; 3: 28–34. [PUBMED]
- Gan L, Lee I, Smith R, et al, Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene. 2000; 257: 119–30. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Harvey T J, Hooper J D, Myers S A, et al, Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem. 2000; 275: 37397–406. [CROSSREF], [PUBMED]
- Yousef G M, Luo L Y, Diamandis E P.. Identification of novel human kallikrein-like genes on chromosome 19q13.3–q13.4. Anticancer Res. 1999; 19: 2843–52. [PUBMED]
- Yousef G M, Chang A, Scorilas A, et al, Genomic organization of the human kallikrein gene family on chromosome 19q13.3–q13.4. Biochem Biophys Res Commun. 2000; 276: 125–33. [CROSSREF], [PUBMED]
- Rittenhouse H G, Finlay J A, Mikolajczyk S D, et al, Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci. 1998; 35: 275–368. [PUBMED]
- Diamandis E P, Yousef G M, Luo L Y, et al, The new human kallikrein gene family: Implications in carcinogenesis. Trends Endocrinol Metab. 2000; 11: 54–60. [CROSSREF], [PUBMED]
- Clements J, Hooper J, Dong Y, et al, The expanded human kallikrein (KLK) gene family: Genomic organisation, tissue-specific expression and potential functions. Biol Chem. 2001; 382: 5–14. [PUBMED]
- Black M H, Diamandis E P.. The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat. 2000; 59: 1–14. [CROSSREF], [PUBMED]
- Becker C, Noldus J, Diamandis E, et al, The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci. 2001; 38: 357–99. [PUBMED]
- Diamandis E P, Yousef G M.. Human tissue kallikrein gene family: A rich source of novel disease biomarkers. Expert Rev Mol Diagn. 2001; 1: 182–90. [PUBMED]
- Diamandis E P, Yousef G M.. Human tissue kallikreins: A family of new cancer biomarkers. Clin Chem. 2002; 48: 1198–205. [PUBMED]
- Stephan C, Jung K, Diamandis E P, et al, Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology. 2002; 59: 2–8. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Yousef G M, Diamandis E P.. Expanded human tissue kallikrein family—a novel panel of cancer biomarkers. Tumour Biol. 2002; 23: 185–92. [CROSSREF], [PUBMED]
- Yousef G M, Diamandis E P.. Kallikreins, steroid hormones and ovarian cancer: Is there a link?. Minerva Endocrinol. 2002; 27: 157–66. [PUBMED]
- Yousef G M, Diamandis E P.. An overview of the kallikrein gene families in humans and other species: Emerging candidate tumour markers. Clin Biochem. 2003; 36: 443–52. [CROSSREF], [PUBMED]
- Lilja H.. Biology of prostate-specific antigen. Urology. 2003; 62: 27–33. [CROSSREF], [PUBMED]
- Luo L Y, Yousef G, Diamandis E P.. Human tissue kallikreins and testicular cancer. APMIS. 2003; 111: 225–32. [PUBMED], [INFOTRIEVE]
- Yousef G M, Diamandis E P.. Tissue kallikreins: New players in normal and abnormal cell growth?. Thromb Haemost. 2003; 90: 7–16. [PUBMED]
- Yousef G M, Diamandis E P.. Human tissue kallikreins: A new enzymatic cascade pathway?. Biol Chem. 2002; 383: 1045–57. [PUBMED]
- Simmer J P, Hu J C.. Expression, structure, and function of enamel proteinases. Connect Tissue Res. 2002; 43: 441–9. [PUBMED]
- Balk S P, Ko Y J, Bubley G J.. Biology of prostate-specific antigen. J Clin Oncol. 2003; 21: 383–91. [CROSSREF], [PUBMED]
- Yousef G M, Kishi T, Diamandis E P.. Role of kallikrein enzymes in the central nervous system. Clin Chim Acta. 2003; 329: 1–8. [CROSSREF], [PUBMED]
- Sharma J N. Does the kinin system mediate in cardiovascular abnormalities? An overview. J Clin Pharmacol. 2003; 43: 1187–95. [CROSSREF], [PUBMED]
- Tomimatsu Y, Idemoto S, Moriguchi S, et al, Proteases involved in long-term potentiation. Life Sci. 2002; 72: 355–61. [CROSSREF], [PUBMED]
- Bhoola K, Ramsaroop R, Plendl J, et al, Kallikrein and kinin receptor expression in inflammation and cancer. Biol Chem. 2001; 382: 77–89. [PUBMED]
- Foussias G, Yousef G M, Diamandis E P.. Identification and molecular characterization of a novel member of the siglec family (SIGLEC9). Genomics. 2000; 67: 171–8. [CROSSREF], [PUBMED]
- Yousef G M, Diamandis M, Jung K, et al, Molecular cloning of a novel human acid phosphatase gene (ACPT) that is highly expressed in the testis. Genomics. 2001; 74: 385–95. [CROSSREF], [PUBMED]
- Baker A R, Shine J.. Human kidney kallikrein: cDNA cloning and sequence analysis. DNA. 1985; 4: 445–50. [PUBMED], [INFOTRIEVE]
- Fukushima D, Kitamura N, Nakanishi S.. Nucleotide sequence of cloned cDNA for human pancreatic kallikrein. Biochemistry. 1985; 24: 8037–43. [PUBMED]
- Schedlich L J, Bennetts B H, Morris B J.. Primary structure of a human glandular kallikrein gene. DNA. 1987; 6: 429–37. [PUBMED]
- Henttu P, Vihko P.. cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes. Biochem Biophys Res Commun. 1989; 160: 903–10. [PUBMED]
- Richards R I, Holman K, Shen Y, et al, Human glandular kallikrein genes: Genetic and physical mapping of the KLK1 locus using a highly polymorphic microsatellite PCR marker. Genomics. 1991; 11: 77–82. [PUBMED]
- Stephenson S A, Verity K, Ashworth L K, et al, Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3–13.4. J Biol Chem. 1999; 274: 23210–4. [CROSSREF], [PUBMED]
- Dihanich M, Spiess M.. A novel serine proteinase-like sequence from human brain. Biochim Biophys Acta. 1994; 1218: 225–8. [CROSSREF], [PUBMED]
- Hansson L, Stromqvist M, Backman A, et al, Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J Biol Chem. 1994; 269: 19420–6. [PUBMED]
- Anisowicz A, Sotiropoulou G, Stenman G, et al, A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med. 1996; 2: 624–36. [PUBMED]
- Liu X L, Wazer D E, Watanabe K, et al, Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 1996; 56: 3371–9. [PUBMED]
- Little S P, Dixon E P, Norris F, et al, Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J Biol Chem. 1997; 272: 25135–42. [CROSSREF], [PUBMED]
- Yamashiro K, Tsuruoka N, Kodama S, et al, Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim Biophys Acta. 1997; 1350: 11–4. [CROSSREF], [PUBMED]
- Yoshida S, Taniguchi M, Hirata A, et al, Sequence analysis and expression of human neuropsin cDNA and gene. Gene. 1998; 213: 9–16. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Yoshida S, Taniguchi M, Suemoto T, et al, cDNA cloning and expression of a novel serine protease, TLSP. Biochim Biophys Acta. 1998; 1399: 225–8. [CROSSREF], [PUBMED]
- Brattsand M, Egelrud T.. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J Biol Chem. 1999; 274: 30033–40. [CROSSREF], [PUBMED]
- Nelson P S, Gan L, Ferguson C, et al, Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci USA. 1999; 96: 3114–9. [CROSSREF], [PUBMED]
- Tanimoto H, Underwood L J, Shigemasa K, et al, The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer. 1999; 86: 2074–82. [CROSSREF], [PUBMED]
- Underwood L J, Tanimoto H, Wang Y, et al, Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res. 1999; 59: 4435–9. [PUBMED]
- Hu J C, Zhang C, Sun X, et al, Characterization of the mouse and human PRSS17 genes, their relationship to other serine proteases, and the expression of PRSS17 in developing mouse incisors. Gene. 2000; 251: 1–8. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Yousef G M, Diamandis E P.. The new kallikrein-like gene, KLK-L2: Molecular characterization, mapping, tissue expression, and hormonal regulation. J Biol Chem. 1999; 274: 37511–6. [CROSSREF], [PUBMED]
- Yousef G M, Scorilas A, Diamandis E P.. Genomic organization, mapping, tissue expression, and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. Genomics. 2000; 63: 88–96. [CROSSREF], [PUBMED]
- Yousef G M, Diamandis E P.. The expanded human kallikrein gene family: Locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). Genomics. 2000; 65: 184–94. [CROSSREF], [PUBMED]
- Yousef G M, Luo L Y, Scherer S W, et al, Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics. 1999; 62: 251–9. [CROSSREF], [PUBMED]
- Yousef G M, Obiezu C V, Luo L Y, et al, Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res. 1999; 59: 4252–6. [PUBMED]
- Yousef G M, Chang A, Diamandis E P.. Identification and characterization of KLK-L4, a new kallikrein-like gene that appears to be down-regulated in breast cancer tissues. J Biol Chem. 2000; 275: 11891–8. [CROSSREF], [PUBMED]
- Yousef G M, Scorilas A, Jung K, et al, Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem. 2001; 276: 53–61. [PUBMED]
- Yousef G M, Scorilas A, Magklara A, et al, The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family—genomic characterization, mapping, tissue expression and hormonal regulation. Gene. 2000; 254: 119–28. [CROSSREF], [PUBMED]
- Luo L, Herbrick J A, Scherer S W, et al, Structural characterization and mapping of the normal epithelial cell-specific 1 gene. Biochem Biophys Res Commun. 1998; 247: 580–6. [CROSSREF], [PUBMED]
- Takayama T K, Carter C A, Deng T.. Activation of prostate-specific antigen precursor (proPSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry. 2001; 40: 1679–87. [CROSSREF], [PUBMED]
- Yousef G M, Magklara A, Diamandis E P.. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics. 2000; 69: 331–41. [CROSSREF], [PUBMED]
- Yousef G M, Magklara A, Chang A, et al, Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res. 2001; 61: 3425–31. [PUBMED]
- Hooper J D, Bui L T, Rae F K, et al, Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics. 2001; 73: 117–22. [CROSSREF], [PUBMED]
- Howles P N, Dickinson D P, DiCaprio L L, et al, Use of a cDNA recombinant for the gamma-subunit of mouse nerve growth factor to localize members of this multigene family near the TAM-1 locus on chromosome 7. Nucleic Acids Res. 1984; 12: 2791–805. [PUBMED]
- Wines D R, Brady J M, Southard E M, et al, Evolution of the rat kallikrein gene family: Gene conversion leads to functional diversity. J Mol Evol. 1991; 32: 476–92. [PUBMED]
- Yamanaka H, He X, Matsumoto K, et al, Protease M/neurosin mRNA is expressed in mature oligodendrocytes. Brain Res Mol Brain Res. 1999; 71: 217–24. [CROSSREF], [PUBMED]
- Chen Z L, Momota Y, Kato K, et al, Expression of neuropsin mRNA in the mouse embryo and the pregnant uterus. J Histochem Cytochem. 1998; 46: 313–20. [PUBMED]
- Backman A, Stranden P, Brattsand M, et al, Molecular cloning and tissue expression of the murine analog to human stratum corneum chymotryptic enzyme. J Invest Dermatol. 1999; 113: 152–5. [CROSSREF], [PUBMED]
- Mitsui S, Okui A, Kominami K, et al, cDNA cloning and tissue–specific splicing variants of mouse hippostasin/TLSP (PRSS20). Biochim Biophys Acta. 2000; 1494: 206–10. [CROSSREF], [PUBMED]
- Wines D R, Brady J M, Pritchett D B, et al, Organization and expression of the rat kallikrein gene family. J Biol Chem. 1989; 264: 7653–62. [PUBMED]
- Chapdelaine P, Gauthier E, Ho-Kim M A, et al, Characterization and expression of the prostatic arginine esterase gene, a canine glandular kallikrein. DNA Cell Biol. 1991; 10: 4959
- Mitsui S, Yamada T, Okui A, et al, A novel isoform of a kallikrein-like protease, TLSP/hippostasin, (PRSS20), is expressed in the human brain and prostate. Biochem Biophys Res Commun. 2000; 272: 205–11. [CROSSREF], [PUBMED]
- Dong Y, Kaushal A, Brattsand M, et al, Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res. 2003; 9: 1710–20. [PUBMED]
- Nakamura T, Mitsui S, Okui A, et al, Alternative splicing isoforms of hippostasin (PRSS20/KLK11) in prostate cancer cell lines. The Prostate. 2001; 49: 72–8. [CROSSREF], [PUBMED]
- Korkmaz K S, Korkmaz C G, Pretlow T G, et al, Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: Intracellular localization, alternative cDNA forms, and regulation by multiple hormones. DNA Cell Biol. 2001; 20: 435–45. [CROSSREF], [PUBMED]
- Riegman P H, Klaassen P, van der Korput J A, et al, Molecular cloning and characterization of novel prostate antigen cDNA's. Biochem Biophys Res Commun. 1988; 155: 181–8. [PUBMED]
- Riegman P H, Vlietstra R J, van der Korput H A, et al, Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol. 1991; 76: 181–90. [CROSSREF], [PUBMED]
- Chen L M, Murray S R, Chai K X, et al, Molecular cloning and characterization of a novel kallikrein transcript in colon and its distribution in human tissues. Braz J Med Biol Res. 1994; 27: 1829–38. [PUBMED]
- Rae F, Bulmer B, Nicol D, et al, The human tissue kallikreins (KLKs 1–3) and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library. Immunopharmacology. 1999; 45: 83–8. [CROSSREF], [PUBMED]
- Liu X F, Essand M, Vasmatzis G, et al, Identification of three new alternate human kallikrein 2 transcripts: Evidence of long transcript and alternative splicing. Biochem Biophys Res Commun. 1999; 264: 833–9. [CROSSREF], [PUBMED]
- Tanaka T, Isono T, Yoshiki T, et al, A novel form of prostate-specific antigen transcript produced by alternative splicing. Cancer Res. 2000; 60: 56–9. [PUBMED]
- Obiezu C V, Diamandis E P.. An alternatively spliced variant of KLK4 expressed in prostatic tissue. Clin Biochem. 2000; 33: 599–600. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Heuze N, Olayat S, Gutman N, et al, Molecular cloning and expression of an alternative hKLK3 transcript coding for a variant protein of prostate-specific antigen. Cancer Res. 1999; 59: 2820–4. [PUBMED]
- Heuze-Vourc'h N, Leblond V, Olayat S, et al, Characterization of PSA-RP2, a protein related to prostate-specific antigen and encoded by alternative hKLK3 transcripts. Eur J Biochem. 2001; 268: 4408–13. [CROSSREF], [PUBMED]
- Dong Y, Kaushal A, Bui L, et al, Human kallikrein 4 (klk4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res. 2001; 7: 2363–71. [PUBMED]
- Myers S A, Clements J A.. Kallikrein 4 (KLK4), a new member of the human kallikrein gene family is up-regulated by estrogen and progesterone in the human endometrial cancer cell line, KLE. J Clin Endocrinol Metab. 2001; 86: 2323–6. [CROSSREF], [PUBMED]
- Magklara A, Scorilas A, Katsaros D, et al, The human KLK8 (neuropsin/ovasin) gene: Identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res. 2001; 7: 806–11. [PUBMED]
- Chang A, Yousef G M, Jung K, et al, Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: Differential expression in the human testis and testicular cancer. Anticancer Res. 2001; 21: 3147–52. [PUBMED]
- David A, Mabjeesh N, Azar I, et al, Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. J Biol Chem. 2002; 277: 18084–90. [CROSSREF], [PUBMED]
- Heuze-Vourc'h N, Leblond V, Courty Y.. Complex alternative splicing of the hKLK3 gene coding for the tumor marker PSA (prostate-specific-antigen). Eur J Biochem. 2003; 270: 706–14. [CROSSREF], [PUBMED]
- Mitsui S, Tsuruoka N, Yamashiro K, et al, A novel form of human neuropsin, a brain-related serine protease, is generated by alternative splicing and is expressed preferentially in human adult brain. Eur J Biochem. 1999; 260: 627–34. [CROSSREF], [PUBMED]
- Nakamura T, Mitsui S, Okui A, et al, Molecular cloning and expression of a variant form of hippostasin/KLK11 in prostate. The Prostate. 2003; 54: 299–305. [CROSSREF], [PUBMED]
- Ohta T, Basten C J. Gene conversion generates hypervariability at the variable regions of kallikreins and their inhibitors. Mol Phylogenet Evol. 1992; 1: 87–90. [PUBMED]
- Bridon D P, Dowell B L.. Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling. Urology. 1995; 45: 801–6. [CROSSREF], [PUBMED]
- Gomis-Ruth F X, Bayes A, Sotiropoulou G, et al, The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family. J Biol Chem. 2002; 277: 27273–81. [CROSSREF], [PUBMED]
- Takada Y, Skidgel R A, Erdos E G.. Purification of human urinary prokallikrein: Identification of the site of activation by the metalloproteinase thermolysin. Biochem J. 1985; 232: 851–8. [PUBMED]
- Angermann A, Rahn H P, Hektor T, et al, Purification and characterization of human salivary-gland prokallikrein from recombinant baculovirus-infected insect cells. Eur J Biochem. 1992; 206: 225–33. [PUBMED]
- Skytt A, Stromqvist M, Egelrud T.. Primary substrate specificity of recombinant human stratum corneum chymotryptic enzyme. Biochem Biophys Res Commun. 1995; 211: 586–9. [CROSSREF], [PUBMED]
- Takayama T K, Fujikawa K, Davie E W.. Characterization of the precursor of prostate specific antigen: Activation by trypsin and by human glandular kallikrein. J Biol Chem. 1997; 272: 21582–8. [CROSSREF], [PUBMED]
- Lu H S, Hsu Y R, Lu L I, et al, Isolation and characterization of human tissue kallikrein produced in Escherichia coli: Biochemical comparison to the enzymatically inactive prokallikrein and methionyl kallikrein. Protein Expr Purif. 1996; 8: 215–26. [CROSSREF], [PUBMED]
- Lu H S, Hsu Y R, Narhi L O, et al, Purification and characterization of human tissue prokallikrein and kallikrein isoforms expressed in Chinese hamster ovary cells. Protein Expr Purif. 1996; 8: 227–37. [CROSSREF], [PUBMED]
- Lovgren J, Rajakoski K, Karp M, et al, Activation of the zymogen form of prostate specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun. 1997; 238: 549–55. [CROSSREF], [PUBMED]
- Kumar A, Mikolajczyk S D, Goel A S, et al, Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 1997; 57: 3111–4. [PUBMED]
- Takayama T K, McMullen B A, Nelson P S, et al, Characterization of hK4 (prostase), a prostate-specific serine protease: Activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry. 2001; 40: 15341–8. [CROSSREF], [PUBMED]
- Kumar A, Goel A S, Hill T M, et al, Expression of human glandular kallikrein, hK2, in mammalian cells. Cancer Res. 1996; 56: 5397–402. [PUBMED]
- Kumar A, Mikolajczyk S D, Hill T M, et al, Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells. The Prostate. 2000; 44: 248–54. [CROSSREF], [PUBMED]
- Mikolajczyk S D, Millar L S, Marker K M, et al, Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2. Eur J Biochem. 1997; 246: 440–6. [PUBMED]
- Lovgren J, Airas K, Lilja H.. Enzymatic action of human glandular kallikrein 2 (hK2): Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors. Eur J Biochem. 1999; 262: 781–9. [CROSSREF], [PUBMED]
- Lovgren J, Tian S, Lundwall A, et al, Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels. Eur J Biochem. 1999; 266: 1050–5. [CROSSREF], [PUBMED]
- Denmeade S R, Lovgren J, Khan S R, et al, Activation of latent protease function of prohK2, but not pro-PSA, involves autoprocessing. The Prostate. 2001; 48: 122–6. [CROSSREF], [PUBMED]
- Magklara A, Mellati A A, Wasney G A, et al, Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun. 2003; 307: 948–55. [CROSSREF], [PUBMED]
- Bernett M J, Blaber S I, Scarisbrick I A, et al, Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem. 2002; 277: 24562–70. [CROSSREF], [PUBMED]
- Sotiropoulou G, Rogakos V, Tsetsenis T, et al, Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol Res. 2003; 13: 381–91. [PUBMED]
- Hervio L S, Coombs G S, Bergstrom R C, et al, Negative selectivity and the evolution of protease cascades: The specificity of plasmin for peptide and protein substrates. Chem Biol. 2000; 7: 443–53. [CROSSREF], [PUBMED]
- Mikolajczyk S D, Millar L S, Kumar A, et al, Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. The Prostate. 1998; 34: 44–50. [CROSSREF], [PUBMED]
- Kapadia C, Chang A, Sotiropoulou G, et al, Human kallikrein 13: Production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem. 2003; 49: 77–86. [CROSSREF], [PUBMED]
- Hsieh M C, Cooperman B S.. The preparation and catalytic properties of recombinant human prostate-specific antigen (rPSA). Biochim Biophys Acta. 2000; 1481: 75–87. [CROSSREF], [PUBMED]
- Bode W, Chen Z, Bartels K, et al, Refined 2 A x-ray crystal structure of porcine pancreatic kallikrein A, a specific trypsin-like serine proteinase: Crystallization, structure determination, crystallographic refinement, structure and its comparison with bovine trypsin. J Mol Biol. 1983; 164: 237–82. [PUBMED], [INFOTRIEVE]
- Katz B A, Liu B, Barnes M, et al, Crystal structure of recombinant human tissue kallikrein at 2.0 A resolution. Protein Sci. 1998; 7: 875–85. [PUBMED]
- Bax B, Blundell T L, Murray-Rust J, et al, Structure of mouse 7S NGF: A complex of nerve growth factor with four binding proteins. Structure. 1997; 5: 1275–85. [CROSSREF], [PUBMED]
- Timm D E. The crystal structure of the mouse glandular kallikrein-13 (prorenin converting enzyme). Protein Sci. 1997; 6: 1418–25. [PUBMED]
- Kishi T, Kato M, Shimizu T, et al, Crystal structure of neuropsin, a hippocampal protease involved in kindling epileptogenesis. J Biol Chem. 1999; 274: 4220–4. [CROSSREF], [PUBMED]
- Carvalho A L, Dias J M, Sanz L, et al, Purification, crystallization and identification by x-ray analysis of a prostate kallikrein from horse seminal plasma. Acta Crystallogr D Biol Crystallogr. 2001; 57: 1180–3. [CROSSREF], [PUBMED]
- Stenman U H, Leinonen J, Alfthan H, et al, A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991; 51: 222–6. [PUBMED]
- Frenette G, Deperthes D, Tremblay R R, et al, Purification of enzymatically active kallikrein hK2 from human seminal plasma. Biochim Biophys Acta. 1997; 1334: 109–15. [CROSSREF], [PUBMED]
- Stephan C, Jung K, Schnorr D, et al, Re: A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol. 2002; 167: 259–60. [PUBMED], [INFOTRIEVE]
- Christensson A, Laurell C B, Lilja H.. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990; 194: 755–63. [PUBMED]
- Lilja H, Christensson A, Dahlen U, et al, Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991; 37: 1618–25. [PUBMED]
- Zhou G X, Chao L, Chao J.. Kallistatin: A novel human tissue kallikrein inhibitor: Purification, characterization, and reactive center sequence. J Biol Chem. 1992; 267: 25873–80. [PUBMED]
- Grauer L S, Finlay J A, Mikolajczyk S D, et al, Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. J Androl. 1998; 19: 407–11. [PUBMED]
- Mikolajczyk S D, Millar L S, Kumar A, et al, Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int J Cancer. 1999; 81: 438–42. [CROSSREF], [PUBMED]
- Mikolajczyk S D, Millar L S, Marker K M, et al, Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue. Cancer Res. 1999; 59: 3927–30. [PUBMED]
- Hutchinson S, Luo L Y, Yousef G M, et al, Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin. Clin Chem. 2003; 49: 746–51. [CROSSREF], [PUBMED]
- Yousef G M, Kapadia C, Polymeris M E, et al, The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. Biochim Biophys Acta. 2003; 1628: 88–96. [CROSSREF], [PUBMED]
- Potempa J, Korzus E, Travis J.. The serpin superfamily of proteinase inhibitors: Structure, function, and regulation. J Biol Chem. 1994; 269: 15957–60. [PUBMED], [INFOTRIEVE]
- Miao R Q, Agata J, Chao L, et al, Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood. 2002; 100: 3245–52. [CROSSREF], [PUBMED]
- Chao J, Miao R Q, Chen V, et al, Novel roles of kallistatin, a specific tissue kallikrein inhibitor, in vascular remodeling. Biol Chem. 2001; 382: 15–21. [PUBMED]
- Roberts R A, Gullick W J.. Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis is increased by expression of a mutant ras oncogene. J Cell Sci. 1989; 94 (Pt 3): 527–35
- Maeda H, Wu J, Okamoto T, et al, Kallikrein-kinin in infection and cancer. Immunopharmacology. 1999; 43: 115–28. [CROSSREF], [PUBMED]
- Maeda H, Fang J, Inutsuka T, et al, Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications. Int Immunopharmacol. 2003; 3: 319–28. [CROSSREF], [PUBMED]
- Wolf W C, Evans D M, Chao L, et al, A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol. 2001; 159: 1797–805. [PUBMED]
- Emanueli C, Zacheo A, Minasi A, et al, Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle. Arterioscler Thromb Vasc Biol. 2000; 20: 2379–85. [PUBMED]
- Emanueli C, Minasi A, Zacheo A, et al, Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation. 2001; 103: 125–32. [PUBMED]
- Emanueli C, Salis M B, Stacca T, et al, Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension. 2001; 38: 136–41. [PUBMED]
- Miao R Q, Chen V, Chao L, et al, Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol. 2003; 284: C1604–13. [PUBMED]
- Rehault S, Monget P, Mazerbourg S, et al, Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem. 2001; 268: 2960–8. [CROSSREF], [PUBMED]
- Tschesche H, Kohnert U, Fedrowitz J, et al, Tissue kallikrein effectively activates latent degrading metalloenzymes. Adv Exp Med Biol. 1989; 247A: 545–8. [PUBMED], [INFOTRIEVE]
- List K, Jensen O N, Bugge T H, et al, Plasminogen-independent initiation of the prourokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice. Biochemistry. 2000; 39: 508–15. [CROSSREF], [PUBMED]
- Iwadate H, Sugisaki T, Kudo M, et al, Actions of insulin-like growth factor binding protein-5 (IGFBP-5) are potentially regulated by tissue kallikrein in rat brains. Life Sci. 2003; 73: 3149–58. [CROSSREF], [PUBMED]
- Hecquet C, Tan F, Marcic B M, et al, Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. Mol Pharmacol. 2000; 58: 828–36. [PUBMED]
- Deddish P A, Hecquet C, Erdos E G, et al, B2R of bradykinin activated by proteases. Hypertension. 2003; 42: e1–2. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Macfarlane S R, Seatter M J, Kanke T, et al, Proteinase-activated receptors. Pharmacol Rev. 2001; 53: 245–82. [PUBMED]
- Lilja H.. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest. 1985; 76: 1899–903. [PUBMED]
- Lilja H, Abrahamsson P A, Lundwall A.. Semenogelin, the predominant protein in human semen: Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem. 1989; 264: 1894–900. [PUBMED]
- Deperthes D, Frenette G, Brillard-Bourdet M, et al, Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl. 1996; 17: 659–65. [PUBMED]
- Espana F, Gilabert J, Estelles A, et al, Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res. 1991; 64: 309–20. [PUBMED]
- Christensson A, Lilja H.. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem. 1994; 220: 45–53. [PUBMED]
- Malm J, Hellman J, Hogg P, et al, Enzymatic action of prostate-specific antigen (PSA or hK3): Substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. The Prostate. 2000; 45: 132–9. [CROSSREF], [PUBMED]
- Obiezu C V, Soosaipillai A, Jung K, et al, Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem. 2002; 48: 1232–40. [PUBMED]
- Diamandis E P, Yousef G M, Soosaipillai A R, et al, Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem. 2000; 33: 369–75. [CROSSREF], [PUBMED]
- Kishi T, Grass L, Soosaipillai A, et al, Human kallikrein 8: Immunoassay development and identification in tissue extracts and biological fluids. Clin Chem. 2003; 49: 87–96. [CROSSREF], [PUBMED]
- Diamandis E P, Okui A, Mitsui S, et al, Human kallikrein 11: A new biomarker of prostate and ovarian carcinoma. Cancer Res. 2002; 62: 295–300. [PUBMED]
- Luo L Y, Grass L, Howarth D J, et al, Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem. 2001; 47: 237–46. [PUBMED]
- Brillard-Bourdet M, Rehault S, Juliano L, et al, Amidolytic activity of prostatic acid phosphatase on human semenogelins and semenogelin-derived synthetic substrates. Eur J Biochem. 2002; 269: 390–5. [CROSSREF], [PUBMED]
- Cohen P, Graves H C, Peehl D M, et al, Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab. 1992; 75: 1046–53. [CROSSREF], [PUBMED]
- Fielder P J, Rosenfeld R G, Graves H C, et al, Biochemical analysis of prostate specific antigen-proteolyzed insulin-like growth factor binding protein-3. Growth Regul. 1994; 4: 164–72. [PUBMED]
- Koistinen H, Paju A, Koistinen R, et al, Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. The Prostate. 2002; 50: 112–8. [CROSSREF], [PUBMED]
- Sutkowski D M, Goode R L, Baniel J, et al, Growth regulation of prostatic stromal cells by prostate-specific antigen. J Natl Cancer Inst. 1999; 91: 1663–9. [CROSSREF], [PUBMED]
- Killian C S, Corral D A, Kawinski E, et al, Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun. 1993; 192: 940–7. [CROSSREF], [PUBMED]
- Russell P J, Bennett S, Stricker P.. Growth factor involvement in progression of prostate cancer. Clin Chem. 1998; 44: 705–23. [PUBMED]
- Yonou H, Aoyagi Y, Kanomata N, et al, Prostate-specific antigen induces osteoplastic changes by an autonomous mechanism. Biochem Biophys Res Commun. 2001; 289: 1082–7. [CROSSREF], [PUBMED]
- Cramer S D, Chen Z, Peehl D M.. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: Inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol. 1996; 156: 526–31. [PUBMED]
- Iwamura M, Hellman J, Cockett A T, et al, Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology. 1996; 48: 317–25. [CROSSREF], [PUBMED]
- Fortier A H, Nelson B J, Grella D K, et al, Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst. 1999; 91: 1635–40. [CROSSREF], [PUBMED]
- Fortier A H, Holaday J W, Liang H, et al, Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. The Prostate. 2003; 56: 212–9. [CROSSREF], [PUBMED]
- Heidtmann H H, Nettelbeck D M, Mingels A, et al, Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer. 1999; 81: 1269–73. [CROSSREF], [PUBMED]
- Charlesworth M C, Young C Y, Miller V M, et al, Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. J Androl. 1999; 20: 220–9. [PUBMED]
- Deperthes D, Marceau F, Frenette G, et al, Human kallikrein hK2 has low kininogenase activity while prostate-specific antigen (hK3) has none. Biochim Biophys Acta. 1997; 1343: 102–6. [CROSSREF], [PUBMED]
- Colman R W, Jameson B A, Lin Y, et al, Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 2000; 95: 543–50. [PUBMED]
- Colman R W.. Role of the light chain of high molecular weight kininogen in adhesion, cell-associated proteolysis and angiogenesis. Biol Chem. 2001; 382: 65–70. [PUBMED]
- Balbay M D, Juang P, Llansa N, et al, Stable transfection of human prostate cancer cell line PC-3 with prostate-specific antigen induces apoptosis both in vivo and in vitro. Proc Am Assoc Cancer Res (Abstract). 1999; 40: 225–6
- Denmeade S R, Litvinov I, Sokoll L J, et al, Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. The Prostate. 2003; 56: 45–53. [CROSSREF], [PUBMED]
- Lai L C, Erbas H, Lennard T W, et al, Prostate-specific antigen in breast cyst fluid: Possible role of prostate-specific antigen in hormone-dependent breast cancer. Int J Cancer. 1996; 66: 743–6. [CROSSREF], [PUBMED]
- Kennedy-Smith A G, McKenzie J L, Owen M C, et al, Prostate specific antigen inhibits immune responses in vitro: A potential role in prostate cancer. J Urol. 2002; 168: 741–7. [PUBMED]
- Aalamian M, Tourkova I L, Chatta G S, et al, Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J Urol. 2003; 170: 2026–30. [PUBMED]
- Fong L, Small E J.. Immunotherapy for prostate cancer. Semin Oncol. 2003; 30: 649–58. [PUBMED]
- Horig H, Lee C S, Kaufman H L.. Prostate-specific antigen vaccines for prostate cancer. Expert Opin Biol Ther. 2002; 2: 395–408. [PUBMED]
- Wolchok J D, Gregor P D, Nordquist L T, et al, DNA vaccines: An active immunization strategy for prostate cancer. Semin Oncol. 2003; 30: 659–66. [PUBMED]
- Xiao-Ya S, Donald S, Phang J M.. Prostate-specific antigen (PSA) stimulates generation of reactive oxygen species (ROS) in LNCaP cells by a nonproteolytic mechanism. Proc Am Assoc Cancer Res (Abstract). 2000; 41: 43
- Sun X Y, Donald S P, Phang J M.. Testosterone and prostate-specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis. 2001; 22: 1775–80. [CROSSREF], [PUBMED]
- Fleury C, Mignotte B, Vayssiere J L.. Mitochondrial reactive oxygen species in cell death signaling. Biochimie. 2002; 84: 131–41. [CROSSREF], [PUBMED]
- Webber M M, Waghray A, Bello D.. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res. 1995; 1: 1089–94. [PUBMED]
- Frenette G, Tremblay R R, Lazure C, et al, Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int J Cancer. 1997; 71: 897–9. [CROSSREF], [PUBMED]
- Simmer J P, Fukae M, Tanabe T, et al, Purification, characterization, and cloning of enamel matrix serine proteinase 1. J Dent Res. 1998; 77: 377–86. [PUBMED]
- Scully J L, Bartlett J D, Chaparian M G, et al, Enamel matrix serine proteinase 1: Stage-specific expression and molecular modeling. Connect Tissue Res. 1998; 39: 111–22, discussion. 41–9. [PUBMED]
- Bartlett J D, Simmer J P, Ryu O H, et al, Proteinases in developing dental enamel: Characterization of recombinant pig enamelysin activity and cleavage of recombinant pig and mouse amelogenins. Crit Rev Oral Biol Med. 1999; 10: 425–41. [PUBMED]
- Hu J C, Ryu O H, Chen J J, et al, Localization of EMSP1 expression during tooth formation and cloning of mouse cDNA. J Dent Res. 2000; 79: 70–6. [PUBMED]
- Ryu O, Hu J C, Yamakoshi Y, et al, Porcine kallikrein-4 activation, glycosylation, activity, and expression in prokaryotic and eukaryotic hosts. Eur J Oral Sci. 2002; 110: 358–65. [CROSSREF], [PUBMED]
- Hu J C, Sun X, Zhang C, et al, Enamelysin and kallikrein-4 mRNA expression in developing mouse molars. Eur J Oral Sci. 2002; 110: 307–15. [CROSSREF], [PUBMED]
- D'Souza R N, Aberg T, Gaikwad J, et al, Cbfa1 is required for epithelial-mesenchymal interactions regulating tooth development in mice. Development. 1999; 126: 2911–20. [PUBMED]
- Scarisbrick I A, Towner M D, Isackson P J.. Nervous system-specific expression of a novel serine protease: Regulation in the adult rat spinal cord by excitotoxic injury. J Neurosci. 1997; 17: 8156–68. [PUBMED]
- Scarisbrick I A, Asakura K, Blaber S, et al, Preferential expression of myelencephalon-specific protease by oligodendrocytes of the adult rat spinal cord white matter. Glia. 2000; 30: 219–30. [CROSSREF], [PUBMED]
- Scarisbrick I A, Isackson P J, Ciric B, et al, MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J Comp Neurol. 2001; 431: 347–61. [CROSSREF], [PUBMED]
- Scarisbrick I A, Blaber S I, Lucchinetti C F, et al, Activity of a newly identified serine protease in CNS demyelination. Brain. 2002; 125: 1283–96. [CROSSREF], [PUBMED]
- Blaber S I, Scarisbrick I A, Bernett M J, et al, Enzymatic properties of rat myelencephalon-specific protease. Biochemistry. 2002; 41: 1165–73. [CROSSREF], [PUBMED]
- Ogawa K, Yamada T, Tsujioka Y, et al, Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. Psychiatry Clin Neurosci. 2000; 54: 419–26. [CROSSREF], [PUBMED]
- Iwata A, Maruyama M, Akagi T, et al, Alpha-synuclein degradation by serine protease neurosin: Implication for pathogenesis of synucleinopathies. Hum Mol Genet. 2003; 12: 2625–35. [CROSSREF], [PUBMED]
- Okui A, Kominami K, Uemura H, et al, Characterization of a brain-related serine protease, neurosin (human kallikrein 6), in human cerebrospinal fluid. Neuroreport. 2001; 12: 1345–50. [PUBMED]
- Chen Z L, Yoshida S, Kato K, et al, Expression and activity-dependent changes of a novel limbic-serine protease gene in the hippocampus. J Neurosci. 1995; 15: 5088–97. [PUBMED]
- Shimizu C, Yoshida S, Shibata M, et al, Characterization of recombinant and brain neuropsin, a plasticity-related serine protease. J Biol Chem. 1998; 273: 11189–96. [CROSSREF], [PUBMED]
- Yoshida S, Shiosaka S.. Plasticity-related serine proteases in the brain (review). Int J Mol Med. 1999; 3: 405–9. [PUBMED]
- Komai S, Matsuyama T, Matsumoto K, et al, Neuropsin regulates an early phase of schaffer-collateral long-term potentiation in the murine hippocampus. Eur J Neurosci. 2000; 12: 1479–86. [CROSSREF], [PUBMED]
- Hirata A, Yoshida S, Inoue N, et al, Abnormalities of synapses and neurons in the hippocampus of neuropsin-deficient mice. Mol Cell Neurosci. 2001; 17: 600–10. [CROSSREF], [PUBMED]
- Tani N, Matsumoto K, Ota I, et al, Effects of fibronectin cleaved by neuropsin on cell adhesion and migration. Neurosci Res. 2001; 39: 247–51. [CROSSREF], [PUBMED]
- Matsumoto-Miyai K, Ninomiya A, Yamasaki H, et al, NMDA-dependent proteolysis of presynaptic adhesion molecule L1 in the hippocampus by neuropsin. J Neurosci. 2003; 23: 7727–36. [PUBMED]
- He X P, Shiosaka S, Yoshida S.. Expression of neuropsin in oligodendrocytes after injury to the CNS. Neurosci Res. 2001; 39: 455–62. [CROSSREF], [PUBMED]
- Akita H, Matsuyama T, Iso H, et al, Effects of oxidative stress on the expression of limbic-specific protease neuropsin and avoidance learning in mice. Brain Res. 1997; 769: 86–96. [CROSSREF], [PUBMED]
- Hoffman K B, Martinez J, Lynch G.. Proteolysis of cell adhesion molecules by serine proteases: A role in long term potentiation?. Brain Res. 1998; 811: 29–33. [CROSSREF], [PUBMED]
- Egelrud T, Lundstrom A.. A chymotrypsin-like proteinase that may be involved in desquamation in plantar stratum corneum. Arch Dermatol Res. 1991; 283: 108–12. [PUBMED]
- Cui C Y, Takahashi M, Tezuka T.. 30-kDa trypsin-like proteases in the plantar stratum corneum. J Dermatol. 1997; 24: 504–9. [PUBMED]
- Ekholm E, Egelrud T.. The expression of stratum corneum chymotryptic enzyme in human anagen hair follicles: Further evidence for its involvement in desquamation-like processes. Br J Dermatol. 1998; 139: 585–90. [CROSSREF], [PUBMED]
- Horikoshi T, Igarashi S, Uchiwa H, et al, Role of endogenous cathepsin D-like and chymotrypsin-like proteolysis in human epidermal desquamation. Br J Dermatol. 1999; 141: 453–9. [CROSSREF], [PUBMED]
- Ekholm E, Egelrud T.. Expression of stratum corneum chymotryptic enzyme in relation to other markers of epidermal differentiation in a skin explant model. Exp Dermatol. 2000; 9: 65–70. [CROSSREF], [PUBMED]
- Simon M, Jonca N, Guerrin M, et al, Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J Biol Chem. 2001; 276: 20292–9. [CROSSREF], [PUBMED]
- Sondell B, Thornell L E, Egelrud T.. Evidence that stratum corneum chymotryptic enzyme is transported to the stratum corneum extracellular space via lamellar bodies. J Invest Dermatol. 1995; 104: 819–23. [PUBMED]
- Inoue N, Kuwae K, Ishida-Yamamoto A, et al, Expression of neuropsin in the keratinizing epithelial tissue-immunohistochemical analysis of wild-type and nude mice. J Invest Dermatol. 1998; 110: 923–31. [CROSSREF], [PUBMED]
- Kitayoshi H, Inoue N, Kuwae K, et al, Effect of 12-O-tetradecanoyl-phorbol ester and incisional wounding on neuropsin mRNA and its protein expression in murine skin. Arch Dermatol Res. 1999; 291: 333–8. [CROSSREF], [PUBMED]
- Kuwae K, Matsumoto-Miyai K, Yoshida S, et al, Epidermal expression of serine protease, neuropsin (KLK8) in normal and pathological skin samples. Mol Pathol. 2002; 55: 235–41. [CROSSREF], [PUBMED]
- Kirihara T, Matsumoto-Miyai K, Nakamura Y, et al, Prolonged recovery of ultraviolet B-irradiated skin in neuropsin (KLK8)-deficient mice. Br J Dermatol. 2003; 149: 700–6. [CROSSREF], [PUBMED]
- Egelrud T.. Stratum corneum chymotryptic enzyme. Barrett A J, Rawlings N P, Woessner J F. Handbook of Proteolytic Enzymes.. Pp. 87–89, London, Academic. 1998
- Nylander-Lundqvist E, Egelrud T.. Formation of active IL-1 beta from pro-IL-1 beta catalyzed by stratum corneum chymotryptic enzyme in vitro. Acta Derm Venereol. 1997; 77: 203–6. [PUBMED]
- Brattsand M, Egelrud T.. Purification and characterization of interleukin 1 beta from human plantar stratum corneum: Evidence of interleukin 1 beta processing in vivo not involving interleukin 1 beta convertase. Cytokine. 1998; 10: 506–13. [CROSSREF], [PUBMED]
- Hansson L, Backman A, Ny A, et al, Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: A model for chronic itchy dermatitis. J Invest Dermatol. 2002; 118: 444–9. [CROSSREF], [PUBMED]
- Wong G W, Yang Y, Yasuda S, et al, Mouse mast cells express the tryptic protease neuropsin/Prss19. Biochem Biophys Res Commun. 2003; 303: 320–5. [CROSSREF], [PUBMED]
- Chapdelaine P, Paradis G, Tremblay R R, et al, High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett. 1988; 236: 205–8. [CROSSREF], [PUBMED]
- Swift G H, Craik C S, Stary S J, et al, Structure of the two related elastase genes expressed in the rat pancreas. J Biol Chem. 1984; 259: 14271–8. [PUBMED]
- Boulet A M, Erwin C R, Rutter W J.. Cell-specific enhancers in the rat exocrine pancreas. Proc Natl Acad Sci USA. 1986; 83: 3599–603. [PUBMED]
- Wolf D A, Schulz P, Fittler F.. Transcriptional regulation of prostate kallikrein-like genes by androgen. Mol Endocrinol. 1992; 6: 753–62. [CROSSREF], [PUBMED]
- Murtha P, Tindall D J, Young C Y.. Androgen induction of a human prostate-specific kallikrein, hKLK2: Characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry. 1993; 32: 6459–64. [PUBMED]
- Cleutjens K B, van der Korput H A, Ehren-van Eekelen C C, et al, A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol. 1997; 11: 1256–65. [CROSSREF], [PUBMED]
- Sun Z, Pan J, Balk S P.. Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate- specific antigen and kallikrein 2 genes. Nucleic Acids Res. 1997; 25: 3318–25. [CROSSREF], [PUBMED]
- Komatsu N, Takata M, Otsuki N, et al, Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages. J Invest Dermatol. 2003; 121: 542–9. [CROSSREF], [PUBMED]
- MacDonald R J, Southard-Smith E M, Kroon E.. Disparate tissue-specific expression of members of the tissue kallikrein multigene family of the rat. J Biol Chem. 1996; 271: 13684–90. [PUBMED]
- Penschow J D, Coghlan J P.. Secretion of glandular kallikrein and renin from the basolateral pole of mouse submandibular duct cells: An immunocytochemical study. J Histochem Cytochem. 1993; 41: 95–103. [PUBMED]
- Schachter M, Peret M W, Moriwaki C, et al, Localization of kallikrein in submandibular gland of cat, guinea pig, dog, and man by the immunoperoxidase method. J Histochem Cytochem. 1980; 28: 1295–300. [PUBMED]
- Henttu P, Vihko P.. Prostate-specific antigen and human glandular kallikrein: Two kallikreins of the human prostate. Ann Med. 1994; 26: 157–64. [PUBMED]
- Petraki C D, Karavana V N, Skoufogiannis P T, et al, The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem. 2001; 49: 1431–41. [PUBMED]
- Petraki C D, Karavana V N, Revelos K I, et al, Immunohistochemical localization of human kallikreins 6 and 10 in pancreatic islets. Histochem J. 2002; 34: 313–22. [CROSSREF], [PUBMED]
- Petraki C D, Karavana V N, Luo L Y, et al, Human kallikrein 10 expression in normal tissues by immunohistochemistry. J Histochem Cytochem. 2002; 50: 1247–61. [PUBMED]
- Petraki C D, Gregorakis A K, Papanastasiou P A, et al, Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis. 2003; 6: 223–7. [CROSSREF], [PUBMED]
- Harvey T J, Dong Y, Bui L, et al, Production and characterization of anti-peptide kallikrein 4 antibodies: Use of computer modelling to design peptides specific to kallikrein 4. Russell P J, Jackson P, Kingsley E A. Prostate Cancers: Methods and Protocols. Pp. 241–54, New Jersey, The Humana Press. 2003
- Cumming A D, Walsh T, Wojtacha D, et al, Expression of tissue kallikrein in human kidney. Clin Sci (Lond). 1994; 87: 5–11
- Sondell B, Thornell L E, Stigbrand T, et al, Immunolocalization of stratum corneum chymotryptic enzyme in human skin and oral epithelium with monoclonal antibodies: Evidence of a proteinase specifically expressed in keratinizing squamous epithelia. J Histochem Cytochem. 1994; 42: 459–65. [PUBMED]
- Ekholm E, Sondell B, Stranden P, et al, Expression of stratum corneum chymotryptic enzyme in human sebaceous follicles. Acta Derm Venereol. 1998; 78: 343–7. [PUBMED]
- Ekholm I E, Brattsand M, Egelrud T.. Stratum corneum tryptic enzyme in normal epidermis: A missing link in the desquamation process?. J Invest Dermatol. 2000; 114: 56–63. [CROSSREF], [PUBMED]
- Figueroa C D, MacIver A G, Mackenzie J C, et al, Localisation of immunoreactive kininogen and tissue kallikrein in the human nephron. Histochemistry. 1988; 89: 437–42. [PUBMED]
- Darson M F, Pacelli A, Roche P, et al, Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker. Urology. 1997; 49: 857–62. [CROSSREF], [PUBMED]
- Vio C P, Figueroa C D, Caorsi I.. Anatomical relationship between kallikrein-containing tubules and the juxtaglomerular apparatus in the human kidney. Am J Hypertens. 1988; 1: 269–71. [PUBMED]
- Borgono C A, Grass L, Soosaipillai A, et al, Human kallikrein 14: A new potential biomarker for ovarian and breast cancer. Cancer Res. 2003; 63: 9032–41. [PUBMED]
- Orstavik T B, Brandtzaeg P, Nustad K, et al, Immunohistochemical localization of kallikrein in human pancreas and salivary glands. J Histochem Cytochem. 1980; 28: 557–62. [PUBMED]
- Elgamal A A, Ectors N L, Sunardhi-Widyaputra S, et al, Detection of prostate specific antigen in pancreas and salivary glands: A potential impact on prostate cancer overestimation. J Urol. 1996; 156: 464–8. [PUBMED]
- Ishikawa T, Kashiwagi H, Iwakami Y, et al, Expression of alpha-fetoprotein and prostate-specific antigen genes in several tissues and detection of mRNAs in normal circulating blood by reverse transcriptase-polymerase chain reaction. Jpn J Clin Oncol. 1998; 28: 723–8. [CROSSREF], [PUBMED]
- Yousef G M, Polymeris M E, Grass L, et al, Human kallikrein 5: A potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 2003; 63: 3958–65. [PUBMED]
- Mahabeer R, Bhoola K D.. Kallikrein and kinin receptor genes. Pharmacol Ther. 2000; 88: 77–89. [CROSSREF], [PUBMED]
- Sawant S, Snyman C, Bhoola K.. Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms. Int Immunopharmacol. 2001; 1: 2063–80. [CROSSREF], [PUBMED]
- Meneton P, Bloch-Faure M, Hagege A A, et al, Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA. 2001; 98: 2634–9. [CROSSREF], [PUBMED]
- Pinto Y M, Bader M, Pesquero J B, et al, Increased kallikrein expression protects against cardiac ischemia. FASEB J. 2000; 14: 1861–3. [PUBMED]
- Silva J A, Jr., Araujo R C, Baltatu O, et al, Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J. 2000; 14: 1858–60. [PUBMED]
- Devani M, Cugno M, Vecchi M, et al, Kallikrein-kinin system activation in Crohn's disease: Differences in intestinal and systemic markers. Am J Gastroenterol. 2002; 97: 2026–32. [CROSSREF], [PUBMED]
- Margolius H S.. Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Clin Rev Allergy Immunol. 1998; 16: 337–49. [PUBMED], [INFOTRIEVE]
- Ueno A, Oh-ishi S.. Roles for the kallikrein-kinin system in inflammatory exudation and pain: Lessons from studies on kininogen-deficient rats. J Pharmacol Sci. 2003; 93: 1–20. [CROSSREF], [PUBMED]
- Skidgel R A, Alhenc-Gelas F, Campbell W B.. Prologue: Kinins and related systems: New life for old discoveries. Am J Physiol Heart Circ Physiol. 2003; 284: 1886–91
- Cassim B, Mody G, Bhoola K.. Kallikrein cascade and cytokines in inflamed joints. Pharmacol Ther. 2002; 94: 1–34. [CROSSREF], [PUBMED]
- Wagner S, Kalb P, Lukosava M, et al, Activation of the tissue kallikrein-kinin system in stroke. J Neurol Sci. 2002; 202: 75–6. [CROSSREF], [PUBMED]
- Raidoo D M, Bhoola K D.. Pathophysiology of the kallikrein-kinin system in mammalian nervous tissue. Pharmacol Ther. 1998; 79: 105–27. [CROSSREF], [PUBMED]
- Bernstein H G.. Tissue kallikrein-like immunoreactive material decorates neuritic plaques of Alzheimer patients. Clin Neuropathol. 1997; 16: 69–71. [PUBMED]
- Naicker S, Naidoo S, Ramsaroop R, et al, Tissue kallikrein and kinins in renal disease. Immunopharmacology. 1999; 44: 183–92. [CROSSREF], [PUBMED]
- Dellalibera-Joviliano R, Reis M L, Donadi E A.. Kinin system in lupus nephritis. Int Immunopharmacol. 2001; 1: 1889–96. [CROSSREF], [PUBMED]
- Stadnicki A, Mazurek U, Plewka D, et al, Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease. Int Immunopharmacol. 2003; 3: 939–44. [CROSSREF], [PUBMED]
- Briseid K, Johannesen S.. Kallikrein modification with affinity to IgG present in higher amounts than normal in plasma from patients with Crohn's disease. Scand J Clin Lab Invest. 2003; 63: 425–9. [PUBMED]
- Jaffa A A, Chai K X, Chao J, et al, Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int. 1992; 41: 789–95. [PUBMED]
- Raidoo D M, Ramsaroop R, Naidoo S, et al, Regional distribution of tissue kallikrein in the human brain. Immunopharmacology. 1996; 32: 39–47. [CROSSREF], [PUBMED]
- Agostoni A, Cugno M.. The kinin system: Biological mechanisms and clinical implications. Recenti Prog Med. 2001; 92: 764–73. [PUBMED]
- Dlamini Z, Raidoo D, Bhoola K.. Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma. Immunopharmacology. 1999; 43: 303–10. [CROSSREF], [PUBMED]
- Shiosaka S, Yoshida S.. Synaptic microenvironments—structural plasticity, adhesion molecules, proteases and their inhibitors. Neurosci Res. 2000; 37: 85–9. [CROSSREF], [PUBMED]
- Diamandis E P, Yousef G M, Petraki C, et al, Human kallikrein 6 as a biomarker of Alzheimer's disease. Clin Biochem. 2000; 33: 663–7. [CROSSREF], [PUBMED]
- Momota Y, Yoshida S, Ito J, et al, Blockade of neuropsin, a serine protease, ameliorates kindling epilepsy. Eur J Neurosci. 1998; 10: 760–4. [CROSSREF], [PUBMED]
- Okabe A, Momota Y, Yoshida S, et al, Kindling induces neuropsin mRNA in the mouse brain. Brain Res. 1996; 728: 116–20. [CROSSREF], [PUBMED]
- Davies B, Kearns I R, Ure J, et al, Loss of hippocampal serine protease BSP1/neuropsin predisposes to global seizure activity. J Neurosci. 2001; 21: 6993–7000. [PUBMED]
- Tomizawa K, He X, Yamanaka H, et al, Injury induces neuropsin mRNA in the central nervous system. Brain Res. 1999; 824: 308–11. [CROSSREF], [PUBMED]
- Shimizu-Okabe C, Yousef G M, Diamandis E P, et al, Expression of the kallikrein gene family in normal and Alzheimer's disease brain. Neuroreport. 2001; 12: 2747–51. [PUBMED]
- Mitsui S, Okui A, Uemura H, et al, Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer's disease. Ann N Y Acad Sci. 2002; 977: 216–23. [PUBMED]
- Zarghooni M, Soosaipillai A, Grass L, et al, Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. Clin Biochem. 2002; 35: 225–31. [CROSSREF], [PUBMED]
- Diamandis E, Scorilas A, Kishi T, et al, Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Clin Biochem. 2004; 37: 230–7. [CROSSREF], [PUBMED]
- Melegos D N, Freedman M S, Diamandis E P.. Prostate-specific antigen in cerebrospinal fluid. Clin Chem. 1997; 43: 855, [PUBMED], [INFOTRIEVE]
- Mannello F, Luchetti F, Falcieri E, et al, Prostate-specific antigen expression in neuroblastoma cell lines. Clin Chem. 1998; 44: 1362–3. [PUBMED], [INFOTRIEVE]
- Johnson B, Horn T, Sander C, et al, Expression of stratum corneum chymotryptic enzyme in ichthyoses and squamoproliferative processes. J Cutan Pathol. 2003; 30: 358–62. [PUBMED]
- Sondell B, Dyberg P, Anneroth G K, et al, Association between expression of stratum corneum chymotryptic enzyme and pathological keratinization in human oral mucosa. Acta Derm Venereol. 1996; 76: 177–81. [PUBMED]
- Ekholm E, Egelrud T.. Stratum corneum chymotryptic enzyme in psoriasis. Arch Dermatol Res. 1999; 291: 195–200. [CROSSREF], [PUBMED]
- Franzke C W, Baici A, Bartels J, et al, Antileukoprotease inhibits stratum corneum chymotryptic enzyme. Evidence for a regulative function in desquamation. J Biol Chem. 1996; 271: 21886–90. [PUBMED]
- Vicanova J, Boyce S T, Harriger M D, et al, Stratum corneum lipid composition and structure in cultured skin substitutes is restored to normal after grafting onto athymic mice. J Investig Dermatol Symp Proc. 1998; 3: 114–20. [PUBMED]
- Ny A, Egelrud T.. Transgenic mice over-expressing a serine protease in the skin: Evidence of interferon gamma-independent MHC II expression by epidermal keratinocytes. Acta Derm Venereol. 2003; 83: 322–7. [CROSSREF], [PUBMED]
- Young C Y, Montgomery B T, Andrews P E, et al, Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res. 1991; 51: 3748–52. [PUBMED]
- Henttu P, Liao S S, Vihko P.. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology. 1992; 130: 766–72. [CROSSREF], [PUBMED]
- Young C Y, Andrews P E, Montgomery B T, et al, Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry. 1992; 31: 818–24. [PUBMED]
- Luke M C, Coffey D S.. Human androgen receptor binding to the androgen response element of prostate specific antigen. J Androl. 1994; 15: 41–51. [PUBMED]
- Cleutjens K B, van Eekelen C C, van der Korput H A, et al, Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem. 1996; 271: 6379–88. [PUBMED]
- Schuur E R, Henderson G A, Kmetec L A, et al, Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem. 1996; 271: 7043–51. [PUBMED]
- Zhang S, Murtha P E, Young C Y.. Defining a functional androgen responsive element in the 5′ far upstream flanking region of the prostate-specific antigen gene. Biochem Biophys Res Commun. 1997; 231: 784–8. [CROSSREF], [PUBMED]
- Yu D C, Sakamoto G T, Henderson D R.. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 1999; 59: 1498–504. [PUBMED]
- Mitchell S H, Murtha P E, Zhang S, et al, An androgen response element mediates LNCaP cell dependent androgen induction of the hK2 gene. Mol Cell Endocrinol. 2000; 168: 89–99. [CROSSREF], [PUBMED]
- Shang Y, Myers M, Brown M.. Formation of the androgen receptor transcription complex. Mol Cell. 2002; 9: 601–10. [CROSSREF], [PUBMED]
- Cleutjens K B, van der Korput H A, van Eekelen C C, et al, An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol. 1997; 11: 148–61. [CROSSREF], [PUBMED]
- Huang W, Shostak Y, Tarr P, et al, Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem. 1999; 274: 25756–68. [CROSSREF], [PUBMED]
- Clements J A, Fuller P.. Tissue kallikrein in the pituitary and brain. Front Neuroendocrinol. 1990; 11: 38–51
- Clements J A, Mukhtar A, Verity K, et al, Kallikrein gene expression in human pituitary tissues. Clin Endocrinol (Oxf). 1996; 44: 223–31
- Fuller P J, Matheson B A, MacDonald R J, et al, Kallikrein gene expression in estrogen-induced pituitary tumors. Mol Cell Endocrinol. 1988; 60: 225–32. [CROSSREF], [PUBMED]
- Powers C A.. Elevated glandular kallikrein in estrogen-induced pituitary tumors. Endocrinology. 1987; 120: 429–31. [PUBMED]
- Corthorn J, Valdes G.. Variations in uterine kallikrein during cycle and early pregnancy in the rat. Biol Reprod. 1994; 50: 1261–4. [PUBMED]
- Valdes G, Figueroa C D, Corthorn J.. Temporospatial changes of kallikrein-like enzymes during the estrous cycle and pregnancy in the rat uterus. Biol Reprod. 1996; 55: 236–45. [PUBMED]
- Corthorn J, Figueroa C, Valdes G.. Estrogen and luminal stimulation of rat uterine kallikrein. Biol Reprod. 1997; 56: 1432–8. [PUBMED]
- Clements J, Mukhtar A, Ehrlich A, et al, Glandular kallikrein gene expression in the human uterus. Braz J Med Biol Res. 1994; 27: 1855–63. [PUBMED]
- Murray S R, Chao J, Lin F K, et al, Kallikrein multigene families and the regulation of their expression. J Cardiovasc Pharmacol. 1990; 15: S7–16. [PUBMED]
- Luo L Y, Grass L, Diamandis E P.. The normal epithelial cell-specific 1 (NES1) gene is upregulated by steroid hormones in the breast carcinoma cell line BT-474. Anticancer Res. 2000; 20: 981–6. [PUBMED]
- Polascik T J, Oesterling J E, Partin A W.. Prostate specific antigen: A decade of discovery—what we have learned and where we are going. J Urol. 1999; 162: 293–306. [PUBMED]
- Partin A W, Hanks G E, Klein E A, et al, Prostate-specific antigen as a marker of disease activity in prostate cancer, Part 1. Oncology (Huntingt). 2002; 16: 1024–38
- Partin A W, Hanks G E, Klein E A, et al, Prostate-specific antigen as a marker of disease activity in prostate cancer, Part 2. Oncology (Huntingt). 2002; 16: 1218–24
- Denmeade S R, Jakobsen C M, Janssen S, et al, Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst. 2003; 95: 990–1000. [CROSSREF], [PUBMED]
- Chakraborty N G, Stevens R L, Mehrotra S, et al, Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother. 2003; 52: 497–505. [CROSSREF], [PUBMED]
- Park H S, Cheon J, Cho H Y, et al, In vivo characterization of a prostate-specific antigen promoter-based suicide gene therapy for the treatment of benign prostatic hyperplasia. Gene Ther. 2003; 10: 1129–34. [CROSSREF], [PUBMED]
- Catalona W J, Partin A W, Slawin K M, et al, Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA. 1998; 279: 1542–7. [CROSSREF], [PUBMED]
- Aleman M, Karakiewicz P I, Kupelian P, et al, Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: Implications for screening. Urology. 2003; 62: 70–4. [CROSSREF], [PUBMED]
- Lein M, Kwiatkowski M, Semjonow A, et al, A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol. 2003; 170: 1175–9. [PUBMED]
- Kurek R, Ylikoski A, Renneberg H, et al, Quantitative PSA RT-PCR for preoperative staging of prostate cancer. The Prostate. 2003; 56: 263–9. [CROSSREF], [PUBMED]
- Tanaka M, Murakami S, Suzuki N, et al, Change in the ratio of free-to-total prostate-specific antigen during progression of advanced prostate cancer. Int J Urol. 2000; 7: 83–7. [CROSSREF], [PUBMED]
- Hilz H, Noldus J, Hammerer P, et al, Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors. Eur Urol. 1999; 36: 286–92. [CROSSREF], [PUBMED]
- Mikolajczyk S D, Millar L S, Wang T J, et al, A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 2000; 60: 756–9. [PUBMED]
- Mikolajczyk S D, Marker K M, Millar L S, et al, A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res. 2001; 61: 6958–63. [PUBMED]
- Herrala A, Kurkela R, Vihinen M, et al, Androgen-sensitive human prostate cancer cells, LNCaP, produce both N-terminally mature and truncated prostate-specific antigen isoforms. Eur J Biochem. 1998; 255: 329–35. [CROSSREF], [PUBMED]
- Mikolajczyk S D, Millar L S, Wang T J, et al, “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology. 2000; 55: 41–5. [CROSSREF], [PUBMED]
- Khan M A, Partin A W, Rittenhouse H G, et al, Evaluation of pro-prostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol. 2003; 170: 723–6. [PUBMED]
- Chan T Y, Mikolajczyk S D, Lecksell K, et al, Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology. 2003; 62: 177–81. [CROSSREF], [PUBMED]
- Mikolajczyk S D, Marks L S, Partin A W, et al, Free prostate-specific antigen in serum is becoming more complex. Urology. 2002; 59: 797–802. [CROSSREF], [PUBMED], [INFOTRIEVE]
- Meng F J, Shan A, Jin L, et al, The expression of a variant prostate-specific antigen in human prostate. Cancer Epidemiol Biomarkers Prev. 2002; 11: 305–9. [PUBMED]
- Henttu P, Lukkarinen O, Vihko P.. Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate. Int J Cancer. 1990; 45: 654–60. [PUBMED]
- Klee G G, Goodmanson M K, Jacobsen S J, et al, Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin Chem. 1999; 45: 800–6. [PUBMED]
- Kwiatkowski M K, Recker F, Piironen T, et al, In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic “gray zone” of total PSA 4 to 10 ng/mL. Urology. 1998; 52: 360–5. [CROSSREF], [PUBMED]
- Recker F, Kwiatkowski M K, Piironen T, et al, The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer. 1998; 83: 2540–7. [CROSSREF], [PUBMED]
- Partin A W, Catalona W J, Finlay J A, et al, Use of human glandular kallikrein 2 for the detection of prostate cancer: Preliminary analysis. Urology. 1999; 54: 839–45. [CROSSREF], [PUBMED]
- Becker C, Piironen T, Pettersson K, et al, Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology. 2000; 55: 694–9. [CROSSREF], [PUBMED]
- Nam R K, Diamandis E P, Toi A, et al, Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol. 2000; 18: 1036–42. [PUBMED]
- Becker C, Piironen T, Pettersson K, et al, Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer. J Urol. 2003; 170: 1169–74. [PUBMED]
- Scorilas A, Plebani M, Mazza S, et al, Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. The Prostate. 2003; 54: 220–9. [CROSSREF], [PUBMED]
- Haese A, Becker C, Noldus J, et al, Human glandular kallikrein 2: A potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. J Urol. 2000; 163: 1491–7. [PUBMED]
- Haese A, Graefen M, Steuber T, et al, Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. The Prostate. 2001; 49: 101–9. [CROSSREF], [PUBMED]
- Haese A, Graefen M, Becker C, et al, The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. The Prostate. 2003; 54: 181–6. [CROSSREF], [PUBMED]
- Saedi M S, Hill T M, Kuus-Reichel K, et al, The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin Chem. 1998; 44: 2115–9. [PUBMED]
- Darson M F, Pacelli A, Roche P, et al, Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology. 1999; 53: 939–44. [CROSSREF], [PUBMED]
- Herrala A M, Porvari K S, Kyllonen A P, et al, Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. Cancer. 2001; 92: 2975–84. [CROSSREF], [PUBMED]
- Slawin K M, Shariat S F, Nguyen C, et al, Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. Cancer Res. 2000; 60: 7142–8. [PUBMED]
- Shariat S F, Kattan M W, Erdamar S, et al, Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol. 2003; 21: 1223–31. [CROSSREF], [PUBMED]
- Shariat S F, Roudier M P, Wilcox G E, et al, Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003; 63: 4662–70. [PUBMED]
- Day C H, Fanger G R, Retter M W, et al, Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera. Oncogene. 2002; 21: 7114–20. [CROSSREF], [PUBMED]
- Goyal J, Smith K M, Cowan J M, et al, The role for NES1 serine protease as a novel tumor suppressor. Cancer Res. 1998; 58: 4782–6. [PUBMED]
- Yousef G M, Scorilas A, Chang A, et al, Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. The Prostate. 2002; 51: 126–32. [CROSSREF], [PUBMED]
- Yousef G M, Stephan C, Scorilas A, et al, Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. The Prostate. 2003; 56: 287–92. [CROSSREF], [PUBMED]
- Nakamura T, Stephan C, Scorilas A, et al, Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. Urology. 2003; 61: 1042–6. [CROSSREF], [PUBMED]
- Stephan C, Yousef G M, Scorilas A, et al, Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J Urol. 2003; 169: 361–4. [PUBMED]
- Nakamura T, Scorilas A, Stephan C, et al, The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res. 2003; 63: 6543–6. [PUBMED]
- Yu H, Diamandis E P.. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem. 1993; 39: 2108–14. [PUBMED]
- Yu H, Diamandis E P.. Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J Urol. 1995; 153: 1004–8. [PUBMED], [INFOTRIEVE]
- Ferguson R A, Yu H, Kalyvas M, et al, Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: Potential applications in prostate and breast cancers. Clin Chem. 1996; 42: 675–84. [PUBMED]
- Diamandis E P.. Prostate specific antigen—new applications in breast and other cancers. Anticancer Res. 1996; 16: 3983–4. [PUBMED]
- Yu H, Diamandis E P, Levesque M, et al, Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996; 40: 171–8. [PUBMED]
- Yu H, Levesque M A, Clark G M, et al, Prognostic value of prostate-specific antigen for women with breast cancer: A large United States cohort study. Clin Cancer Res. 1998; 4: 1489–97. [PUBMED]
- Borchert G H, Melegos D N, Tomlinson G, et al, Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer. 1997; 76: 1087–94. [PUBMED]
- Yu H, Giai M, Diamandis E P, et al, Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 1995; 55: 2104–10. [PUBMED]
- Yu H, Diamandis E P.. Prostate-specific antigen in milk of lactating women. Clin Chem. 1995; 41: 54–8. [PUBMED], [INFOTRIEVE]
- Diamandis E P, Yu H, Sutherland D J.. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat. 1994; 32: 301–10. [PUBMED]
- Howarth D J, Aronson I B, Diamandis E P.. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer. 1997; 75: 1646–51. [PUBMED]
- Sauter E R, Daly M, Linahan K, et al, Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1996; 5: 967–70. [PUBMED]
- Mannello F, Gazzanelli G.. Prostate-specific antigen (PSA/hK3): A further player in the field of breast cancer diagnostics?. Breast Cancer Res. 2001; 3: 238–43. [CROSSREF], [PUBMED]
- Magklara A, Scorilas A, Lopez-Otin C, et al, Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid. Clin Chem. 1999; 45: 1774–80. [PUBMED]
- Black M H, Magklara A, Obiezu C, et al, Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. Br J Cancer. 2000; 82: 361–7. [PUBMED]
- Yousef G M, Scorilas A, Kyriakopoulou L G, et al, Human kallikrein gene 5 (KLK5) expression by quantitative PCR: An independent indicator of poor prognosis in breast cancer. Clin Chem. 2002; 48: 1241–50. [PUBMED]
- Luo L Y, Diamandis E P, Look M P, et al, Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer. 2002; 86: 1790–6. [CROSSREF], [PUBMED]
- Dhar S, Bhargava R, Yunes M, et al, Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin Cancer Res. 2001; 7: 3393–8. [PUBMED]
- Chang A, Yousef G M, Scorilas A, et al, Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: An independent indicator of favourable prognosis in breast cancer. Br J Cancer. 2002; 86: 1457–64. [CROSSREF], [PUBMED]
- Yousef G M, Borgono C A, Scorilas A, et al, Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br J Cancer. 2002; 87: 1287–93. [CROSSREF], [PUBMED]
- Yousef G M, Scorilas A, Nakamura T, et al, The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer. Breast Cancer Res Treat. 2003; 78: 149–58. [CROSSREF], [PUBMED]
- Yousef G M, Yacoub G M, Polymeris M E, et al, Kallikrein gene downregulation in breast cancer. Br J Cancer. 2004; 90: 167–72. [CROSSREF], [PUBMED]
- Yousef G M, Scorilas A, Magklara A, et al, The androgen-regulated gene human kallikrein 15 (KLK15) is an independent and favourable prognostic marker for breast cancer. Br J Cancer. 2002; 87: 1294–300. [CROSSREF], [PUBMED]
- Obiezu C V, Scorilas A, Katsaros D, et al, Higher human kallikrein gene 4 (klk4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res. 2001; 7: 2380–6. [PUBMED]
- Kim H, Scorilas A, Katsaros D, et al, Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer. 2001; 84: 643–50. [CROSSREF], [PUBMED]
- Tanimoto H, Underwood L J, Shigemasa K, et al, Increased expression of protease M in ovarian tumors. Tumour Biol. 2001; 22: 11–8. [CROSSREF], [PUBMED]
- Diamandis E P, Yousef G M, Soosaipillai A R, et al, Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin Biochem. 2000; 33: 579–83. [CROSSREF], [PUBMED]
- Kyriakopoulou L G, Yousef G M, Scorilas A, et al, Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin Biochem. 2003; 36: 135–43. [CROSSREF], [PUBMED]
- Kishi T, Grass L, Soosaipillai A, et al, Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 2003; 63: 2771–4. [PUBMED]
- Yousef G M, Kyriakopoulou L G, Scorilas A, et al, Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: A new independent and favorable prognostic marker. Cancer Res. 2001; 61: 7811–8. [PUBMED]
- Luo L Y, Katsaros D, Scorilas A, et al, Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res. 2001; 7: 2372–9. [PUBMED]
- Shvartsman H S, Lu K H, Lee J, et al, Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol. 2003; 90: 44–50. [CROSSREF], [PUBMED]
- Yousef G M, Polymeris M E, Yacoub G M, et al, Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 2003; 63: 2223–7. [PUBMED]
- Yousef G M, Scorilas A, Katsaros D, et al, Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J Clin Oncol. 2003; 21: 3119–26. [CROSSREF], [PUBMED]
- Yousef G M, Fracchioli S, Scorilas A, et al, Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol. 2003; 119: 346–55. [PUBMED]
- Borgono C A, Fracchioli S, Yousef G M, et al, Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int J Cancer. 2003; 106: 605–10. [PUBMED]
- Clements J, Mukhtar A.. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab. 1994; 78: 1536–9. [CROSSREF], [PUBMED]
- Valdes G, Germain A M, Corthorn J, et al, Tissue kallikrein and bradykinin B2 receptor in human uterus in luteal phase and in early and late gestation. Endocrine. 2001; 16: 207–15. [CROSSREF], [PUBMED]
- Matsumoto-Miyai K, Kitagawa R, Ninomiya A, et al, Decidualization induces the expression and activation of an extracellular protease neuropsin in mouse uterus. Biol Reprod. 2002; 67: 1414–8. [PUBMED]
- Katsu Y, Takasu E, Iguchi T.. Estrogen-independent expression of neuropsin, a serine protease in the vagina of mice exposed neonatally to diethylstilbestrol. Mol Cell Endocrinol. 2002; 195: 99–107. [CROSSREF], [PUBMED]
- Yousef G M, Obiezu C V, Jung K, et al, Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology. 2002; 60: 714–8. [CROSSREF], [PUBMED]
- Luo L Y, Rajpert-De Meyts E R, Jung K, et al, Expression of the normal epithelial cellspecific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer. 2001; 85: 220–4. [CROSSREF], [PUBMED]
- Young C L, Barker W C, Tomaselli C M, et al, Serine proteases. Dayhoff M O. Atlas of Protein Sequence and Structure, National Biomedical Research Foundation. Pp. 73–81, Maryland, Silver Springs. 1978
- Obiezu C V, Scorilas A, Magklara A, et al, Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001; 86: 1558–61. [CROSSREF], [PUBMED]
- Malatesta M, Mannello F, Sebastiani M, et al, Differential distribution of soluble and complexed forms of prostate-specific antigen in cyst fluids of women with gross cystic breast disease. J Clin Lab Anal. 2001; 15: 81–6. [CROSSREF], [PUBMED]
- Wald N J, Hackshaw A K, Diamandis E P, et al, Maternal serum prostate-specific antigen and Down syndrome in the first and second trimesters of pregnancy. International Prenatal Screening Research Group. Prenat Diagn. 1999; 19: 674–6. [CROSSREF], [PUBMED]
- Li B, Goyal J, Dhar S, et al, CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res. 2001; 61: 8014–21. [PUBMED]
- Yunes M J, Neuschatz A C, Bornstein L E, et al, Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery. Int J Radiat Oncol Biol Phys. 2003; 56: 653–7. [CROSSREF], [PUBMED]
- Scorilas A, Borgono C A, Harbeck N, et al, Human kallikrein 13 protein in ovarian cancer cytosols: A new favorable prognostic marker. J Clin Oncol. 2004; 22: 678–85. [PUBMED]